15% Growth, 6% Profit—Where Eureka Forbes' Leverage Went
Reported earnings pop 47% on a one-time gratuity reversal. Strip that, and pre-exceptional profit is up just 6%—revealing a company trading margin for growth with profit leverage risk baked into FY30 targets.
₹57.0 Cr
+47.3% YoY
₹41.0 Cr
+6.1% YoY
₹700.4 Cr
+15.2% YoY
6.1% vs 15.2%
Material shortfall
On the headline, Eureka Forbes' Q1 profit surged 47.3% to ₹57 crore—a pop that signals momentum. Strip the one-time gratuity reversal gain of approximately ₹16 crore, and pre-exceptional profit sits at ₹41 crore, up just 6.1% against 15.2% revenue growth. That gap is the quarter's real story: a company trading margin for growth, and not yet generating the profit leverage needed to support its FY30 ambitions (2x revenue, 3x EBITDA). The market saw it clearly: post-result the stock fell 1.95% on day 1 and extended to −4.42% by day 3.
Where the profit came from
Management claims checked against the result
Revenue grew 15.3% YoY to ₹701 Cr
Delivered ₹700.4 Cr at 15.2% YoY growth
Supported
Water purifier grew by high teens with double-digit volume growth
Product business high-teens growth confirmed; exact water purifier % not separately disclosed
Supported
Pre-exceptional PAT grew 6.1% YoY to ₹41 Cr
Reported PAT ₹57 Cr includes ~₹16 Cr one-time gratuity reversal. Pre-exceptional indeed ₹41 Cr (+6.1%)
Supported but concerning
EBITDA margin 10.5%, down 46 bps with growth investments
Confirmed; gross margin also down 131 bps from commodity/forex. Margin compression structural, not cyclical
Supported; signal negative
Service revenue in line with prior quarters despite 3-12% price hike
Confirmed at ~2.7% growth YoY; bookings softer due to customer deferrals
Supported; growth decelerated
Market share gains in water despite competitive intensity
Stated by management; no external verification. Organic growth vs. supply-constrained competitors is narrative
Supported but unvalidated
What changed on this call
Three strategy shifts reveal underlying pressure: First, service double-digit growth guidance quietly vanished. Prior calls expected service to accelerate; now management reframes as 'two drivers' (AMC + filters) with no numeric commitment—a silent downgrade. Second, FY27 margin guidance is to 'hold' (not expand), despite a prior FY26 call promising margin expansion on efficiency. A 15% revenue quarter typically drives margin expansion; management's defensive posture signals either compressed pricing power or intractable cost headwinds. Third, efficiency programs are now the margin lever—AI, data-driven waste elimination, cost clinicals—a signal that pricing is capped and operational excellence is the only path forward.
The market's verdict: sell-off and position trim
Post-result, the stock fell 1.95% on day 1, extending to −4.42% by day 3. Today it trades at ₹419.85, down 37.18% from its all-time high of ₹668.3, and below its 20-day (₹447.08), 50-day (₹454.26), and 200-day (₹511.1) moving averages. RSI sits at 34.8 (neutral). Foreign institutional investors—the marginal buyer—trimmed their stake 41bp quarter-on-quarter to 13.25%, the second consecutive trim. On a 15% revenue quarter, the price action and flow don't lie: the market agrees that headline growth masks margin pressure and profit-leverage risk.
The bull case
Solid 15.2% revenue growth, broad-based across water, robotics, emerging categories
Water purifiers growing high-teens with double-digit volume; market share gains noted
Robotics, air purifiers, softeners all accelerating; ₹1,000 Cr robotics ambition by FY30
D2C platform at 2.5M monthly active users; cross-sell to 15M customer base largely untapped (<1% multi-category ownership)
Net cash ₹425 Cr; strong balance sheet for long-term investments and strategic moves
FY26 track record: started -46 bps margins, ended +55 bps; management can expand on scale
The bear case is equally substantive:
Pre-exceptional PAT growth only 6.1% vs revenue 15.2%—critical leverage gap at the start of FY27
Gross margin down 131 bps YoY; commodity/forex headwinds persistent with 'no meaningful relief expected in FY27'
EBITDA margin down 46 bps; guidance to 'hold' (not expand) signals no near-term upside despite growth
Service revenue at ~2.7% growth; bookings soft post 3-12% AMC price hike; recovery timeline uncertain
A&SP spending up 21.4%, outpacing 15.2% revenue growth; operating leverage not materializing yet
Pricing power capped; management explicitly avoiding further hikes to protect growth momentum
Ranked risks (for a holder)
Profit leverage collapse
HighPAT growing 6.1% vs revenue 15.2% is a material execution shortfall. If this gap persists, FY30 targets (3x EBITDA on 2x revenue) are at material risk. Efficiency programs must close it, and Q1 shows they haven't yet.
Gross margin structural compression
HighDown 131 bps YoY with 'no meaningful relief' expected in FY27. Commodity/forex headwinds ongoing. Cost-saving programs the only lever. Limited pricing power to offset. Margin floor is the key unknown.
Service deferral and recovery timing
Medium-HighAMC bookings soft post price hike. Management expects 'normalization over time' tied to 18-month tenure lag. If deferral is structural (customers switching/downtrading), profit impact is larger than forecast. Deferred liability provides tailwind but not solution.
Competitive intensity in water purifiers
MediumNew entrants emerging and matching filter-life innovations (competitors matched Eureka's Q1 move within 30 days). Market share gains now; pricing power eroding. Need innovation velocity to sustain share in a growing category.
Emerging category scaling execution
MediumRobotics ₹1,000 Cr by FY30 (40%+ CAGR) is ambitious. Market still nascent; competitive entry likely as size grows. D2C advantage is real but not durable against well-funded entrants. Execution on premiumization and retail expansion critical.
The debate
What to watch next
1 · Pre-exceptional PAT in Q2 FY27
Must re-accelerate closer to revenue growth rate (ideally >12%) to validate margin guidance and FY30 profit targets. If it remains the number to track.
2 · Service revenue recovery (Q2–Q3 FY27)
Watch for normalization from ~2.7% growth post price-hike deferral window. Target to beat: 8%+ growth by Q3 to signal sustainable trajectory. If service remains <5%, deferral was deeper than management admits.
3 · Gross margin stabilization (H2 FY27)
Commodity/forex relief unlikely, so success = cost-saving programs delivering offsets. Target to beat: get back to 59%+ by Q4 to show margin floor holds. Operating leverage must show up in efficiency, not just on revenue.
The close
Eureka Forbes is a solid, consistent franchisee with market leadership in water purifiers and credible long-term ambitions. But Q1 FY27 reveals a company caught in the middle of two forces: revenue accelerates (15.2%), but profit limps (6.1% pre-exceptional). The one-time gratuity gain masked the gap; post-result, the market called it—FII trimmed, the stock sold 4.42% by day 3, and it's now down 37% from all-time high.
Until pre-exceptional PAT growth matches revenue growth—or management raises profit guidance on the back of emerging category scale—the stock remains vulnerable to higher interest rates and earnings disappointment. Efficiency programs and operating leverage must deliver. Margin guidance to 'hold' (not expand) in a 15% growth quarter is not confidence-building.
For a holder: monitor Q2 pre-exceptional PAT (target >12%) and service recovery (target >8%). For a potential buyer: wait for evidence that profit leverage is repairing. The number to track from here is organic PAT in Q2. It will tell whether this is Q1 upfront investment (as management argues) or a structural margin squeeze that caps upside to FY30 targets.
Informational and educational content only. Not investment advice.